22NW LP’s Harvard Bioscience HBIO Stock Holding History

22NW LP’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-19,033	Closed	-$581K	–	97
2016 Q4	$581K	Buy	+19,033	New	+$484K	0.35%	87

Other funds holding HBIO

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPC

Glacier Peak Capital Bellevue, Washington $96.2M AUM 0.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

22NW LP's HBIO Position: Q1 2017 in Review

22NW LP sold out of Harvard Bioscience (HBIO) in Q1 2017, closing a stake of 19,033 shares — an estimated $581K sold.

22NW LP first reported a position in HBIO in Q4 2016 and held it in 1 quarter. The position peaked at $581K in Q4 2016. 62 funds tracked by Wall St. Rank hold HBIO as of Q1 2017.

22NW LP reported no remaining Harvard Bioscience position as of Q1 2017 after selling out during the quarter.
22NW LP sold 19,033 Harvard Bioscience shares in Q1 2017, an estimated $581K.
22NW LP first reported a position in Harvard Bioscience in Q4 2016 and held it in 1 quarter.
22NW LP's Harvard Bioscience position peaked at $581K in Q4 2016.
62 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2017.

Based on 22NW LP's 13F filing for Q1 2017, filed 15 May 2017.